Clinical trial NCT00068068: Photodynamic Therapy With Talaporfin Sodium (LS11) in Treating Patients With Refractory Colorectal Liver Metastases
Official title: Safety and Efficacy of Treating Refractory Cancers With the Litx™ System: Phase II Safety and Efficacy Study in Patients With Liver Metastases From Colorectal Cancer That Have Failed Chemotherapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Liver Metastasis
Colorectal Neoplasms
Liver Neoplasms
Neoplasm Metastasis
Keywords: Photodynamic therapy
Liver metastases
Colorectal cancer
Litx™
Light Infusion Technology™
Talaporfin sodium
LS11
Liver mets
Metastatic colorectal cancer
Light emittting diodes (LED)
Tumor ablation
Combination therapy
Lead sponsor: Light Sciences LLC
Sponsor class: INDUSTRY
First posted: 2003-09-08
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the Litx platform is safe and effective in the treatment of liver metastasis arising from colorectal cancer. Litx is a next-generation photodynamic therapy platform in which the drug, talaporfin sodium (LS11), is activated by light from the light-emitting diode (LED)-based light infusion device, inserted directly into the tumor through the skin prior to treatment.

Detailed description: Patients that provide Informed Consent and satisfy the Eligibility Criteria will undergo CT or ultrasound guided percutaneous placement of a single, two, three, or four light infusion devices depending on their tumor characteristics. No more than 4 light sources will be used at a single treatment. The light infusion devices may be used in a single lesion or in multiple lesions.

Following radiographic confirmation of light infusion device placement, patients will receive an intravenous dose of LS11 at 40 mg/m². One hour following completion of LS11 administration, delivery of 200 J/cm light energy will begin. The light infusion device will then be manually removed and the patients will be observed for acute complication of light infusion device removal. Precautions for protection from external light exposure should be instituted beginning with the LS11 administration and be maintained as defined throughout the study period. On day 30+5 the patient will undergo clinical assessment and the tumor mass will be imaged using contrast enhanced spiral CT for determination of volume and radius of the tumor size, as well as tumor necrosis. The patient may then receive 5-FU and/or leucovorin + either irinotecan or oxaliplatin standard chemotherapy at day 30 visit. All patients, with or without chemotherapy at day 30, will undergo final clinical assessment and final tumor imaging evaluation using contrast CT at day 60+5 of Litx treatment.

Eligibility criteria: Inclusion Criteria

* Patients with metastatic liver lesions from colorectal disease who have failed or progressed on a chemotherapy regimen for metastatic disease.
* Biopsy proven evidence of colorectal cancer.
* Patients with 4 or fewer lesions greater than 1 cm and with no single lesion greater than 7 cm in maximum diameter.
* Age greater than or equal to 18 years.
* Patients must be able to sign informed consent.
* Life expectancy greater than or equal to 3 months.
* ECOG performance status 0-2.
* Patients with extrahepatic disease in addition to their hepatic metastases are eligible and will receive systemic therapy for their extrahepatic disease following Litx therapy.
* Off chemotherapy for 4 weeks. Must have recovered from the chemotherapy effects.

Exclusion Criteria

Patients must be excluded if any of the following apply:

* Patients who are candidates for complete surgical resection.
* Pregnancy or breast-feeding. A negative pregnancy test (urine or serum) is required prior to enrollment.
* Known uncontrollable serious reactions such as anaphylaxis, to the contrast agents used in this study.
* PT or PTT greater than 1.5X control.
* Platelet count less than 100,000.
* WBC less than 2500/mm.
* Neutrophils less than 2000/mm.
* Hemoglobin less than 9 g/dL.
* Liver enzymes greater than 3 X ULN.
* Total bilirubin greater than 1.5 X ULN.
* Serum creatinine greater than 2.5 X ULN.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: HealthOne Alliance/Presbyterian St. Lukes Medical Center
state: Colorado
city: Greenville
country: United States
facility: Eastern Carolina University, School of Medicine
state: North Carolina
city: Philadelphia
country: United States
facility: University of Pennsylvania / Department of Radiation Oncology
state: Pennsylvania
city: Pittsburgh
country: United States
facility: Allegheny General Hospital
state: Pennsylvania
city: Seattle
country: United States
facility: Virginia Mason Medical Center
state: Washington
city: Frankfurt am Main
country: Germany
facility: University Hospital Frankfurt, Johann Wolfgang Goethe-University
Study officials:
References:
citation: Chen J, Keltner L, Christophersen J, Zheng F, Krouse M, Singhal A, Wang SS. New technology for deep light distribution in tissue for phototherapy. Cancer J. 2002 Mar-Apr;8(2):154-63. doi: 10.1097/00130404-200203000-00009.
citation: Lustig RA, Vogl TJ, Fromm D, Cuenca R, Alex Hsi R, D'Cruz AK, Krajina Z, Turic M, Singhal A, Chen JC. A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 2003 Oct 15;98(8):1767-71. doi: 10.1002/cncr.11708.